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Abstract
IgE and not IgG is usually associated with allergy. IgE lodged onmast cells in skin or
gut and basophils in the blood allows for the prolonged duration of allergy through
the persistent expression of high affinity IgE receptors. However, many allergic
reactions are not dependent on IgE and are generated in the absence of allergen
specific and even total IgE. Instead, IgG plasma cells are involved in induction of,
and formuch of the pathogenesis of, allergic diseases. The pattern of IgG producing
plasma cells in atopic children and the tendency for direct or further class switching
to IgE are the principle factors responsible for long-lasting sensitization of mast
cells in allergic children. Indirect class switching from IgG producing plasma cells
has been shown to be the predominant pathway for production of IgE while a Th2
microenvironment, genetic predisposition, and the concentration and nature of
allergens together act on IgG plasma cells in the atopic tendency to undergo further
immunoglobulin gene recombination. The seminal involvement of IgG in allergy is
further indicated by the principal role of IgG4 in the natural resolution of allergy
and as the favourable immunological response to immunotherapy. This paper will
look at allergy through the role of different antibodies than IgE and give current
knowledge of the nature and role of IgG antibodies in the start, maintenance and
resolution of allergy.
Introduction
IgE and not IgG is usually associated with allergy. Allergic
sensitization is conventionally thought of as the establishment of
a population of IgE making plasma cells which induce the
degranulation of vasoactive amines from gut, skin, or lung mast
cells andbloodbasophils and cationic proteins fromeosinophils.
IgE lodged on mast cells and basophils through the prolonged
expression of high affinity IgE receptors allows for the protracted
duration of allergic. But the initial allergic symptoms may
originate from the pathogenesis of IgGproducingB cell clones to
allergens. The frequency of B cells in allergic children switching
from IgG to IgE production may be the critical difference in
atopic children that enables priming of mast cells and basophils.
However, many allergic reactions are not dependent on
IgE and are generated in the absence of allergen specific and
even total IgE. Instead, IgG plasma cells are involved in
induction of allergy. It has been shown lately that B cells start
secreting IgG but are disposed in allergic people either by an
inherent genetic disposition or experience in the womb or
soon after birth, resulting in a Th2 polarized immune
reaction to allergenic compounds that generates class
switching of initially IgG secreting B cells to produce IgE,
thereby potentiating an allergic or anaphylactic reaction.
Additionally, IgG may be involved in the resolution of
allergy. IgG4, in particular, is produced or correlates with
desensitization of allergy by immunotherapy. The structure
of IgG4 enables the blockading of IgG receptors and, because
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IgG4 is unstable and mops up antigen in blood as a
monovalent protein, there is reduced free allergen to
stimulate IgE on sensitized mast cells and basophils. IgG4
also reacts with FcgIIb, the inhibitory immunoglobulin
receptor present on monocytes, macrophages, and dendritic
cells and reduced allergic reactions through the production
of IL-10. Thus, the induction, the pathology or the
resolution of allergy entail other factors than specific IgE
to allergens. Allergic reactions involve a large number of
factors and the formation of allergic conditions involves IgG
in the establishment of atopy, the generation of clinical
symptoms of allergy and in the amelioration of the response
and resolution of allergy. The pattern of IgG producing
plasma cells in atopic children and the tendency for direct or
further class switching to IgE are the seminal events that
generate long-lasting sensitization of mast cells in allergic
children. This paper will look at allergy through the role of
antibodies other than IgE and give current knowledge of the
nature and role of IgG antibodies in the start, maintenance,
and resolution of allergy.
Background
Immunoglobulins of all classes, but especially immunoglob-
ulin G (IgG), are induced as part of the natural exposure to
allergens daily. Peanut, milk, and other natural allergens
provoke antibody responses, particularly IgG, to incidental
ingestion and each person has their own distinct and variable
repertoire of antibodies to their diet and environment.
Antibody levels to different foods vary greatly in different
children despite similar exposure or diet but levels of
immunoglobulin G class or subclass antibodies can be
associated with levels of allergy and Th2 cytokine responses
to sensitising allergens [1]. In mice anaphylaxis can be
mediated by IgG antibodies, acting through the low-affinity
IgG receptor on macrophages to release PAF (platelet
activating factor), inducing smooth muscle contraction and
increased vascular permeability in a very similar way to
histamine [2]. In humans, anaphylaxis has been repeatedly
observed in patients with specific IgG but no detectable IgE
antibody when treated with variety of intravenous immu-
noglobulins (for IgA-deficiency), monoclonal antibodies,
dextran, aprotinin, and von Willebrand factor [3]. In
addition, elevated immunoglobulin G antibodies character-
ize a number of autoimmune inflammatory syndromes,
including rheumatoid arthritis (RA) [4, 5] and systemic
lupus erythematosus (SLE) in which the pathology
recapitulates the immune damage generated in allergy. In
RA, an antibody against the Fc portion of IgG forms the
autoantibody or rheumatoid factor (RF) that forms immune
complexes that contribute to the disease process [6].
Alterations of the T cell receptor z chain, with heightened
affinity for cell activating IgG1 and IgG3 antibodies, enhance
T helper cell activation of B cells and decreased regulatory
function in in the pathology of SLE [7]. It is thought that
approximately a third to half of allergic reactions to foods
may involve IgE-independent mechanisms, such as type II,
type III, or type IV hypersensitivity reactions, leading to such
allergic symptoms as serum sickness, hives, joint pains, and
rashes. Both basophils and mast cells can be triggered by
complement though receptors for anaphylatoxins C3a and
C5a. Therefore, symptoms of allergy can occur in a range of
inflammatory diseases and can be caused by IgG or other
IgE-independent mechanisms.
Sensitization to allergens usually starts in the early
maturation of the individual immune system with the
development of B cell clones producing specific antibodies of
IgE class that continue to trigger reactivity on the surface of
mast cells and basophils where they are docked in high
affinity receptors [8]. Why some children develop IgE to
allergenic compounds and others do not and why IgE in
some children induces clinical allergy when others have
specific IgE without clinical reactivity are still highly
controversial. Are IgE producing plasma cells that generate
clinical symptoms, such as anaphylaxis or systemic capillary
dilation and shock in allergic children, induced in atopic
individuals to undergo further class switching by Th2
conditions [9] or is the nature of these allergens such that it
triggers development of IgE producing B cells bypassing IgG
production? Is there something special about shape or
chemical reactivity of molecules such as Ara I in peanuts and
Fel d1 in cat dander that induce a B cell development
particularly to IgE? Several prominent allergens have
enzymatic properties, suggesting that proteolytic enzymes
invading parasites secrete that break down connective tissue
and allow the parasite access to host tissues, may be
particularly active at promoting Th2 responses. Dust mite
(Dermatophagoides pteronyssinus) Der p 1 is able to cleave
CD23 (FceRII, the low-affinity IgE receptor) and CD25 (IL-2
receptor a-chain) expressed on the surface of some
leukocytes [10], leading to dysregulation of the immune
response and enhanced production of IgE [11]. However, no
general homology in small sequences of 10–15 residues
across allergen families emerges and no consensus sequence
for an allergenic epitope has been found to date [12].
IgM and subsequently IgG are produced predominantly in
the first exposure to an allergen. The majority of people have
a conventional immunoglobulin reaction to allergenic
substances, mainly in the form of Immunoglobulin G
antibodies of the five immunoglobulin classes (Table 1), and
only a few undergo a process of B cell differentiation that
results in the fully class switched plasma cell producing IgE.
IgE-producing plasma cells in peripheral blood are of very
low frequency in normal donors (0.06% of all plasma cells)
and rise in atopic patients (0.32%) in patients with high IgE
levels (average 7.21%) and hyper-IgE patients (6.54%) [13].
IgG in the induction, pathology, and resolution of allergy T. H. Scott-Taylor et al.
14 © 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
The presence of a range of Fcg receptors on a variety of
haematopoietic cells allows IgG subclasses to differentially
activate various cells (Table 1) and provoke a range of
immune responses.
Th2 cytokines, such as IL-4, binding to receptors activate
STAT6 (signal transducer and activator of transcription 6),
leading to phosphorylation by JAK kinases, homodimeriza-
tion, and binding to the Ie promoter [14, 15] that controls
immunoglobulin heavy chain class switching to IgE. LPS
stimulation and CD40 signalling by T cells provides other
inducible IgE transcription factors, includingNF-kB, and act
synergistically to activate transcription of IgE [16]. The
formation of IgE in B cells can be followed by PCR
sequencing of heavy chain genes, with remnants of Sg1
sequences in the rearranged Sm-S heavy gene junctions in IgE
producing B cells indicating indirect class switching via
preliminary IgG production. It has been shown that mature
B cells stimulated with IL-4 in the presence of anti-CD40
antibody produce IgG1 for several hours before a switch to
IgE while immature, transitional B cells switch preferentially
directly to IgE [17]. Most IgE switching occurs sequentially
from IgG1 or IgG3 production to IgE in a second step [18]
which has critical consequences for the affinity of allergen
antibodies. Allergen specific B cells in lymph nodes are
activated by follicular helper T cells to undergo proliferation
during which mutations in the sequence of the variable,
antigen-binding complementarity-determining regions
(CDR, Fig. 1), several per generation, are formed, altering
the binding specificity and affinities of lymph node
generated antibodies [19]. IgE expressing B cells are excluded
from germinal centers and do not undergo hypermutation
and T cell selection and proliferation [20]. B cells that switch
indirectly to IgE production would have undergone somatic
hypermutation and affinity selection during the IgG stage
[21] and generate higher affinity IgE when switched
subsequently. The means of exposure to allergen is also
important; patients who develop severe allergic reactions to
food are often sensitized through damaged skin in early
infancy [22]. Epidermal dendritic cells (Langerhans cells)
thymic stromal lymphopoietin (TSLP) and IL-33 to food
allergens induces Th2 cell-mediated allergic inflammation in
the gastrointestinal tract and the emigration of mast cell
progenitors which drive allergic gut reactions through IL-9
production upon further allergen ingestion [23]. So, early
class switching to IgE of immature B cells in the respiratory
mucosa of children who develop allergic rhinitis and in the
GI tract of children who develop food allergy and atopic
asthma might be a function of when the B cells are first
exposed to the sensitising allergen [24].
Classical allergic sensitization is customarily associated
with elevated IgE antibodies generated by class switched B
cells in bone marrow and in atopic lymph nodes. Circulating
IgE from class switched plasma cells in the bone marrow and
blood lodges on high affinity FceRI receptors on the surface
of basophils and mast cells in tissues, potentiating an
immediate hypersensitivity response. Then, contact with the
allergen triggers specific IgE lodged on receptors to stimulate
mast cell and basophil degranulation and the release of
vasoactive amines and other reagents that induce the
symptoms of clinical allergy. The IgE-coated cells are
sensitized to the allergen [25] and can generate a clinical
response. Most allergens, excepting food allergens, are
relatively small, highly soluble proteins that are carried on
desiccated particles such as pollen grains or mite feces that
diffuse into the mucosa on contact with the airways. It has
been estimated that the maximum exposure to the most
common pollen allergens in ragweed (Artemisia artemisii-
folia) airborne pollen concentrations as low as 6–9 grains/m3
can produce symptoms of asthma in sensitized children [26].
Despite these minute doses, allergic sensitization causing
irritating and even life-threatening Th2-driven immune
responses via specific IgE to these allergens is increasingly
prevalent, with rates of allergen sensitisation in children
approaching 40–50% globally [27].
Table 1. Function of immunoglobulins in allergy.
Antobody
subclasses IgM IgD IgG 1 1,2,3,4 IgA 1,2 IgE
Serum conc.
mg/mL (%)
1.5 (8.1) 0.03
(0.2)
13.5 (72.9) 3.5 (18.9) 0.00005 (>0.001)
Complement
activation
þþþ þþþ þ  
Placental
Transfer
  þ  
External
Secretions
Maternal milk,
nasal secretions
 Maternal milk, nasal secretions Maternal milk, nasal
secretions, tears, saliva

Cellular
interaction
(Fc receptor)
DC, monocyte
(FCmRI)
 Monocyte, macrophage, DC, B cell,
neutrophil, eosinophil, (FcgRI, II, III)
Macrophage, DC,
neutrophil, eosinophil
(FcaRI)
Mast cell, basophil, DC, monocyte,
eosinophil, (FceRI) Bcell,
T cell, eosinophil,
macrophage (FceRII)
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A distinct form of IgE receptor, with different affinities and
expression patterns on immune cells, contributes to the
longevity of clinical allergy. The low-affinity IgE receptor
(FceRII; CD23) is expressed on the surface of B cells, as well as
other hematopoietic cells, while the high-affinity IgE receptor
(FceR1) is expressed onmast cells and basophils (Table 1) as a
tetramer (a, b, and 2 gmolecules) and on antigen presenting
cells, at much lower levels, as trimers (a and 2 g molecules).
Free IgE has a very short half-life but once bound to FceR1, is
expressed for the life of the cell [28]. FceR1 density of
expression on mast cells is proportional to the concentration
of elevated free IgE levels and enhanced by IL-4, C3a, and C5a
complement components through C3aR and C5aR (CD88)
receptors, nerve growth factor through TRKA receptor, and
IgG through FcgR1.Mast cells activated by TLR ligands, such
as TLR3 by double-stranded RNA, induces IFN-g production
[29], indicating that the mode of mast cell activation can
promote or modify allergic sensitization through the high
affinity IgE receptor FceRI. One of the principal immunolog-
ical effects of IFNg is the induction ofMHC class II molecules
on macrophages. Toll receptor stimulation of mast cells and
basophils, principally viaTLR2activation by proteases such as
Der p 1 and hookworm antigens, forms the predominant
source of IL-4 in allergen and helminth parasite-activated
PBMCs, suggesting an evolutionary role for basophils and
mast cells in antigen presentation in MHC class II molecules
and for inductionof IL-4 production andTh2 responses in the
immunity to parasite infection [30, 31].
Syndromes that mimic allergic reactions, such as food
allergy in atopic dermatitis patients and food protein-
induced enterocolitis syndrome (FPIES) are not dependent
on IgE and are generated in the absence of allergen specific
and even total IgE. Since basophils express both activating
and deactivating Fcg receptors, including FcgRI and
FcgRIIb (Table 2), as well as complement receptors FcgC3a
and FcgC5 clinical symptoms can be induced by degran-
ulation caused by IgG antibodies. Thus, IgG antibodies in
RA and SLE and diabetes and allergy generate pathology
through interaction with mast cells and basophils [32].
Evidence indicates that most atopic people start off with a
normal broad distribution of food directed IgG secreting B
cells but are disposed in certain situations, either by an
inherent genetic disposition or experience in the womb or
soon after birth to generate a Th2 polarized immune reaction
to allergenic compounds, causing a class switch toward
mature plasma cells producing IgE. The tendency for the
plasma cells to undergo further class switching beyond IgG
in atopic individuals and the nature of allergenic epitopes in
inducing specific IgE reactions will be established by
advances in current immunogenetics techniques in sequenc-
ing individual and clonal B cell IGH gene sequences in
populations of sensitized and allergic children [33]. These
technologies will determine how antibody triggering of the B
cells that generate allergic symptoms through basophil and
mast cell receptors in atopically disposed children occurs and
why certain B cells switch to well targeted, high affinity,
Figure 1. B Cell Maturation and Antibody Class Switching. A: The heavy gene on chromosome 22 consists of many alternative V, D, and J sequences
which are deleted except for one sequence each as a loop of excised chromosomal DNA in a process of recombination during B cell maturation in the
bone marrow. In the mature B cell the antibody class genes are spliced by switch regions against the chosen VDJ sequence to generate and full antibody
protein carried on the surface. In allergy IgE switched B cells can be generated indirectly via IgG producing B cells or switch directly to IgE production. B:
Antibody switching in mature B cells is inﬂuenced by cytokines produced by T helper cells. IFNg generates IgG1 and IgG3 secreting plasma cells in the
blood while IL4 may generate either IgG4 or IgE producing cells.
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specific IgE with the same conformational specificity of the
germinal center, hypermutated IgG1 or IgG3 antibody to the
inducing allergen, causing the sensitization that sets allergic
children apart. How this seminal event of sensitizing IgE
class switching can be avoided in vulnerable children or
reversed by immunotherapy treatment of allergic children
may emerge from better knowledge of the events that lead to
IgG subclass differentiation.
Finally, as regards the cycle of allergy, it is IgG4, in
particular, that is produced or correlates with desensitization
of allergy by oral immunotherapy or AIT. IgG4 has an
unstable structure and some estimates are that the majority
of antigen bound IgG4 is present as monovalent halves of
antibody that detach at the intrachain disulphide bond
present in the hinge region (Fig. 2). Monovalent IgG4
antigen complexes are unable to bind and crosslink Fcg
receptors and fail to stimulate APC activation but can bind
to FcgIIb receptors and induce downregulation of mast cells
and monocytes and macrophages [34]. Allergy involves
several interlocking factors but begins with the production of
IgG to allergens during natural exposure and deviates in
atopic individuals to form terminally switched B cells
capable of induction of an allergic response. Alternative class
switching to IgG4 can contribute to the natural amelioration
of an allergic response and be provoked in immunotherapy
by stimulation of IgG4 production. The resolution of allergy
may depend on the generation of IgG4 antibodies that
counter sensitising IgE antibodies to allergens.
Allergic process and the involvement of
immunoglobulins
The problem with associating an individual immunological
effector in allergy is unequivocally separating the individual
actions of themany immune factors in pathogenesis. Human
sera contain a mixture of antibodies of different classes and
subclasses produced by B cells with a wide range of
specificities and clonal sizes. B-1a cells, resident on pleural
and peritoneal surfaces in older mice, generate natural
antibodies whereas B-1b cells in the spleen marginal zone
and some mucosal surfaces pick up some microbial
polysaccharides, glycolipids, and a few commensal and
infectious microorganism antigens [35], including flaggelin,
without CD4þ Th cell assistance of any sort. However, these
thymus independent antigens are not often associated with
allergy. Most well-known food allergens are presented in the
normal fashion by ligation of B-2 cells when they crosslink
surface antibody (IgM or IgD), and are reabsorbed,
processed, and re-presented on the surface in the context
of MHC molecules to CD4þ Th cells in germinal centers.
The polarization of Th cells in germinal centers in atopic
individuals is thought to set off amplification and terminal
class switching of further plasma cells to generate allergicTa
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responses to allergens. A lack of exposure to microorganisms
in infancy in a relatively sterile modern environment is
thought to leave modern children with inadequate Th1 or
inflammatory challenge and primed to respond in Th2
allergic or anti-parasitic immune response [36].
B-1 lymphocytes generate from stem cells in foetal and
early neonatal immunity and tend to become localized to
peritoneal and pleural cavities in adult mice. These
lymphocytes are primarily induced by high molecular
weight antigens with low degradability with repeating
epitopes, such as bacterial capsular polysaccharides, that
elicit rapid antibody responses by multivalent BCR cross-
linking in the absence of major histocompatibility complex
class II-restricted T cell help [37]. B-1 cells thus produce
natural IgM in the absence of CD4þ cell interaction [38] as a
first line of defence against a broad spectrum of infections,
such as encapsulated bacteria. B-2 lymphocytes, on the other
hand, emerge from bone marrow later in life, to produce
high-affinity, monospecific class-switched immunoglobulin
that provides long-lived serological memory. B-2 cells
typically encounter antigen first in the lymph node and
proliferate oligoclonally from germinal centers. B-1 lym-
phocyte targets, so called T independent antigens, are only
very infrequently sensitising allergens as it is thought to be
the polarized micro-conditions in na€ve lymph nodes in
allergically disposed individuals that cause differentiation of
mature B-2 cells beyond IgG or directly to IgE producing
plasma cells. B-2 cells are selected by the binding of antigen
to clonally distributed B cell receptors (BCRs; membrane-
bound antibody), triggering signalling cascades that result in
B cell activation [39]. Cross-linked surface antibodies on
immature B-2 cells in nascent germinal centers in lymph
nodes and spleen are incorporated when bindingmultivalent
cognate antigen and follicular T cells stimulate B cell
amplification and IGH rearrangements on chromosome 22.
Primary induction of antibodies including IgE occurs in
lymph nodes local to exposure. In rats repeated treated with
aerosolized ovalbumin generated specific IgE plasma cells
first and foremost in the anterior and posterior mediastinal
lymph nodes of the lower respiratory tract [40]. IgG, IgA,
Figure 2. Modular Structure of an IgG antibody. Antibodies are composed of globular domains, 4 per heavy chain, heavy-chain variable (VH), ﬁrst,
second and third constant (CH1, CH2, and CH3) domains, 2 per light chain, variable (VL) and constant (CL) domains, held together in a strong barrel
shape by intrachain disulphide bonds. Light and heavy chains are linked by interchain disulphide bonds. Different domains have different functions, the
top domain of both the light and heavy chains carry unique complementarity determining regions (CDR) which project and interact with antigen as loops
of unique sequence. Interaction with complement or cellular receptors is the function of CH2 and CH3 domains comprising the Fc portion of antibody.
The serine residue at position 228 in the hinge region and the arginine at position 409 within the CH3 domain of IgG4 are indicated.
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and IgE are produced locally in humans too as shown by the
predominance of specific antibodies to pollen in nasal
secretion in hay fever [41]. However, follicular T cells (Tfh),
a subset of regulatory T cells expressing chemokine receptor
CXCR5 as well as costimulatory molecules ICOS and CD40L
[42] inhibit switching to IgE and may not be conducive to
the formation of allergy [43]. Tfh principally produce IL-21,
a cytokine closely related to IL-2 and IL-15 which reduced
IgE responses and T cell production of Th cytokines to
ovalbumin when administered intranasally to mice [44]. In
IL-4-stimulated mouse B cells, IL-21 down-regulated IgE
production by inhibition of germ line epsilon transcription
[45] but when administered to human PBMC stimulated
with anti-CD40 antibody and cultured with IL-4, IL-21
enhanced IgE production and the formation of plasma cells
[46]. Therefore, the restriction of Tfh to the formation of IgE
in human does not appear to be as absolute as in mice and a
Th2 cytokine microenvironment could potentiate the
formation of IgE producing plasma cells in lymph nodes.
There are still many uncertainties about the formation and
interaction of Tfh and Th cells in lymph nodes in the
development of allergy
IgE-producing plasma cells may have two origins; they
may originate from an immature IgM-producing B
lymphocyte transformed directly to IgE secreting plasma
cells or from an IgG producing intermediate mature B cell
in bone marrow or lymph nodes that has already met its
cognate antigen or allergen. Immature lymphocytes
triggered by allergens would initially produce weak
antibodies with poor affinity in comparison to IgE-
producing cells derived via indirect switching that have
undergone affinity maturation as an IgG producing clone.
Evidence suggests that most IgE plasma cells are derived
from previously antigen-experienced B cells rather than
naive B cells. DNA sequencing of 15,843,270 of immuno-
globulin heavy gene rearrangements of B cells from allergic
and normal children expressing IgE gave results consistent
with indirect switching to IgE from IgG or IgA expressing
B cells [33], suggesting that allergen specificity and affinity
of IgE in allergy is generated by somatic mutation of
preformed immunoglobulin products. Isotype switching
frequencies were similar in healthy and allergic subjects
which indicates that atopic individuals do not generate
higher specific IgE concentrations and wider specificities
than non-atopic children through intrinsic differences in
B cells [33].
The class of immunoglobulin produced by B cells is
determined by two signals; CD40L ligation provided by CD4
T cells and specific cytokines which activate the promotor of
particular immunoglobulin isotypes. Different cytokines
direct the differentiation of early B cells and the recombina-
tion of the heavy chain class genes on chromosome 22 in
particular ways (Fig. 2A). Tfh and perhaps Th cells in local
lymph node germinal differentiate when presented with a
specific cognate antigen, they secrete cytokines and thereby
stimulate a class switch in adjacent B cells. The regulation of
IgG subclass switching of murine B cell by CD4þ CD25þ
cells T helper cells has been very well studied in mouse
models of allergy and it is evident that the ability of specific
cytokines to generate specific differentiation is highly
controlled in mice (Fig. 2B). IFNg applied to mouse mixed
peripheral blood cells in culture in vitro strongly predisposes
to the production of IgG2a antibody producing plasma cells
[47, 48]. While there is a clear distinction in mice between
three lineages of Th cells; Th1 cells producing IFNg and IL-2,
Th2 cells producing IL-4 and IL-5 [49], and Th17 cells
producing IL-17 [50], IL-21 and IL-22, in humans there is
some interchange and variation between these cytokine
producing Th cells. IFNg producing Th1 cells also promote
IgG1 and IgG3 antibodies in humans and elevated Th2
polarized cells in atopic individuals generate more IgG4 and
IgE production [51]. But additional discrete T helper cell
subsets are involved in human allergy; Th9 cells, induced by
TGF-b and IL-4, secrete IL-9 which enhances the growth of
mast cells, and can lead to inflammation in the lung and
intestines, including intestinal anaphylaxis. IL-9, in combi-
nation with TGF-b, can induce the development of Th17
cells which are found in the lungs of patients with severe
asthma and in the skin of patients with chronic atopic
dermatitis. So, in human allergy, while it is probably true
that the cytokine microenvironment of the lymph node
predominantly affects the activation and shaping of the
adaptive immune system, there are influences, including the
innate immune system [52] and the degranulation of mast
cells and basophils and the activation of eosinophils, that
induce an atopic autocrine cycle of cytokine and antibody
polarization, leading to higher level of Th2 cells and higher
levels of IgE in atopic individuals [53].
Mast cells, the principal effector cell in allergy, release
various vasoactive substances, including histamine, SSRA
(slow reacting factor of anaphylaxis), and serotonin when
triggered by IgE class immunoglobulin to allergens. A large
range of pre-formed immunomodulating molecules such as
kinins and proteases are also released from secretory
granules. Leukotrienes, prostaglandins, and PAF (platelet
activated factor) are synthesized by activated mast cells from
arachidonic acid. A whole raft of cytokines (IL-1, IL-2, IL-5,
IL-6, IL-8, IL-9, IL-13, IL-17, TNFa, and TGF-b1),
chemokines (CCL1, CCL2, CCL3, CCL3L1 CCL4, CCL5,
CCL7, CCL8, CCL11, CXCL2) and growth factors (VEGF,
PDGF, bFGF, EGF, IGF-1, and NGF) are synthesized de
novo and released soon after activation [54]. Besides the
dramatic effects of vasodilation in immediate hypersensitiv-
ity and anaphylaxis, mast cells have many homeostatic
functions, including blood coagulation and flow, smooth-
muscle contraction and intestinal peristalsis, wound healing.
T. H. Scott-Taylor et al. IgG in the induction, pathology, and resolution of allergy
© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 19
The secretion of these factors influences the recruitment,
survival, development and function of granulocytes, macro-
phages and dendritic cells and affects both innate and
adaptive immune responses, as well as peripheral tolerance
and autoimmunity. By inducing T and B lymphocyte
activation, mast cells influence the initiation, magnitude,
and maintenance of immune responses and autoimmunity
[52]. Many of self-antigens that react with IgE are homologs
of environmental antigens, including actin binding protein,
profilin, serum albumin, collagen and desmoplakin, and
responses to these are thought to result from cross-reactivity
[55]. It is possible that inflammation associated with IgE-
dependent mast cell degranulation to environmental
allergens induces tissue damage and, in a Th2 dominated
immune environment, allows these self-antigens, no longer
sequestered from the immune system, to elicit an IgE
response [56].
Immunoglobulin triggered mast cells, through the release
of histamine and prostaglandins, also induce the down-
regulation of IL-12 and stimulate the production of IL-10 by
dendritic cells, resulting in a decrease in expression of IFNg
and an increase in IL-4 by T cells [57, 58]. IL-10 also affects B
cells, resulting in class switching to IgG4 and suppression of
IgE production in peripheral B cells [59]. Macrophages may
be greater sources of IL10 and can be stimulated to produce
IL10 by IgG4 antibody binding to FcgRIIb. IL-10 production
by CD4þCD25þ allergen-specific Tr1 (regulatory T) cells, B
cells and monocytes induces and correlates with the
production of IgG4 and the increase in IgG4/IgE ratio in
allergen and peptide immunotherapies in allergy and
autoimmune diseases [60–62] and are thought to underlie
the induction of tolerance to allergens [63]. However, in
allergy, once established, high levels of IgG and IgE
producing plasma cells present in peripheral blood of
allergic and atopic children persist. The IgE response is
further amplified by basophils, mast cells, and eosinophils,
which all express FceRI, (although eosinophils require
activation) and cell-surface CD40L and secrete IL-4, thereby
driving class switching and IgE production by B cells. Long-
lived IgE response in allergy are not due to IgE memory cells,
but are prolonged because plasma cells in the bone marrow
can survive for many years [64]. The half-life of mast cell
docked IgE on sensitized cells has a much longer duration
than free IgG or IgE, resulting in clinical reactivity
continuing for the life of antibody sensitized cells.
Immunoglobulin G and involvement in allergy
Human IgG (Fig. 2) is comprised of four subclasses with
different properties and functions as a result of their
different heavy chains. The IgG1 constitutes some 65% of the
total IgG, with IgG2 forming about 22%, IgG3 about 7%,
and IgG4 only about 4% of the total IgG in serum [65].
Different functions are conferred by various binding
affinities to Fc receptors on different cells (Table 2). All
four subclasses of IgG cross to protect the newborn in the
first months of life. Placenta cells in contact with maternal
blood express FcRn receptors that bind of all four subclasses
of IgG molecules equally [66]. Bound antibodies are then
taken up by receptor-mediated endocytosis, transported
across the cell in vesicles and released into the foetal blood
through the basal membrane by polar transcytosis. Infant
antibodies in the first 1 or 2 months of life thus follow the
serum concentration of maternal IgG antibodies (72% IgG1,
24% IgG3), allowing a period of passive protection for the
maturation of immune cells and the amplification of cellular
defences before the maternal IgG fades away.
IgG1 and IgG3 antibodies activate complement and clear
the majority of pathogens through opsonization and uptake
by macrophages, neutrophils, basophils, and monocytes.
IgG3 is the strongest complement activator, followed by
IgG1 while IgG2 can only activate complement in the
presence of high concentrations of antigen and IgG4 does
not activate complement at all [67]. IgG2 is producedmainly
in response to thymus-independent antigens [68, 69], while
IgG4, and IgE, are usually produced only in helminth
infection or on exposure to allergens [67].
B cells mature in bone marrow, rearranging the sequences
of heavy and light chain genes on chromosomes 22, 2, and 14,
respectively, by recombination, splicing together V, D (heavy
only), and J segments to form an antibody sequence unique to
each B cell by the time it emerges into blood. Cytokines
secreted by a T helper cell in antigen presentation binding to
the IgD or IgM antibody docked on the surface of a na€ve B cell
can generate antibody class switching and proliferation of the
cognate B cell in an interaction that usually occurs in
secondary lymphoid tissue like lymph nodes or spleen. VDJ
genes on chromosome 22 are stimulated to recombine with
different C regions of the heavy chain gene sequence by switch
recombination with deletion of the intervening DNA (Fig.
1A). The mechanism by which mature B cells arrive at the
subclass of antibody they secrete (Fig. 1B) is not well
determined in humans. The greatest detail about the
regulation of IgG subclass switching comes from studies in
mice. Murine peripheral blood mononuclear cells (PBMC)
provoke IgG2a production by B cells upon the addition of
IFNg to the cell culture [48]. Murine inflammatory Th1 cells,
CD4 T helper cells secreting IFNg, generate IgG1 and IgG3,
while murine Th2 cells are associated with generation of IgG4
[51] but the associations are less direct and only partly
understood in humans. IL17, produced by Th17 cells [70] has
been associated with IgG1 and IgG3 production by human B
cells [71] while humanB cells produce IgG4 and IgEwhen IL4
is added to a PBMC culture in vitro [72, 73], supporting the
premise that IgG4 production also occurs in humans by
interaction with Th2-like cells.
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The antibody sequence still retains some plasticity in a
productive plasma cell. Somatic mutation occurs at a high
rate in the mature Ig gene segments of proliferating cells and
B cells expressing mutated antibody with improved antigen
binding are favored by closer interaction with T cells and
higher stimulation through the Fc receptor of the surface
antibody. As an immune response progresses, particularly as
the free concentration of antigen concentration falls,
mutation generates diverse antibodies but those with higher
affinity are selected through greater stimulation of the B
cells.
Self-reactive IgG and IgE antibodies are commonly
detected in both allergic and autoimmune diseases and
contribute to the pathogenesis of atopic dermatitis, RA,
systemic lupus erythematosus, Hashimoto’s thyroiditis,
Graves’ disease, BP and MS, and their animal models
[74–77]. In atopy, these autoreactive antibodies are
primarily detected in those individuals with severe and
chronic diseases such as atopic dermatitis, where cytokine
regulation of B cell class switching is less regulated that in
patients with more mild respiratory symptoms [74]. High
affinity receptor for class IgE antibodies on sensitized
monocytes, eosinophils, basophils, and mast cells accounts
for the prolonged continuation of allergic sensitization, the
distinctive symptoms of allergic reaction and much of the
long-term pathology of intermittent allergic exposure. But
the presence of both IgG and IgE antibody receptors
indicates that both classes of antibodies are involved in the
pathogenesis of allergy and common autoimmune diseases
and that dysregulation of class switching in a range of
autoimmune and atopic diseases generates pathogenic
antibodies. Many of the self-antigens that react with IgE
are homologs of environmental antigens, including the actin
binding protein, profilin, serum albumin, collagen, and
desmoplakin, and responses to these are thought to result
from cross-reactivity. There is speculation that inflamma-
tion associated with IgE-dependent mast cell responses to
environmental allergens induces tissue damage and in a Th2
dominated immune environment these self-antigens, no
longer sequestered from the immune system, elicit an IgE
response [78].
It may be the very low dose of aerosolized antigens such as
pollens and mite antigens that may help polarize the
response toward Th2 and the production of IgE. The most
efficient antigen-presenting cells in the respiratory mucosa
are myeloid or conventional dendritic cells (con. DC, Table
2) which take up and process the majority of small soluble
protein antigens delivered at low dose. Skin borne con. DC
migrate to regional lymph nodes and cause differentiation
that favors the differentiation of Th2 cells [79].
There is also evidence that the destruction initiated by
mast cells and basophils degranulation, possibly by IgG
antibodies, generates conditions that favor Th2 cytokine
production and class switching to allergen specific IgE.
Eosinophil chemotactic factor A released as one of these early
phasemediators attracts eosinophils into the area which then
release late phase mediators including PGE2 and leuko-
trienes which generate much more powerful hypersensitivity
type I responses, causing an atopic autocrine cycle of
cytokine and antibody polarization that influences the IgG
subclass toward IgE production [53]. Perhaps the polarized
immune system of an atopic mother causes polarisation of
children in utero, shaping the cytokine induction of B cells in
allergen specific germinal centers in the same way as a lack of
inflammatory experience in early childhood has the
potential to generate a tendency to respond in a Th2 skewed
immune response (hygiene hypothesis; Strachan [80]). An
additional influence in the higher rate of IgE class switching
is the repetitive, multi-epitope nature, the stability, and
indigestibility of allergenic proteins that stimulates the
prestimulated IgG producing cells into further class-switch-
ing on repeated encounters. Immature B cells may switch
more directly from IgM to IgE secretion when exposed to
certain allergen conformations in early infancy and the
suggestion that early exposure to allergens accounts for
higher rates of IgE class switching in atopic and allergic
children.
IgG4 and role in allergy
Human IgG is comprised of four subclasses, each with its
own properties and biological functions, as determined by
the different heavy chains. IgG1 constituting 65% of the total
IgG, IgG2 forming 20%, IgG3 some 7%, and IgG4 only
about 4% of the total IgG in blood [65]. The IgG subclasses
differ in their Fc receptor affinity and their ability to activate
the complement system. IgG1 and IgG3 antibodies are
complement activating and opsonize and cause uptake of
invading microorganisms by macrophages by interaction
with FcgRI and FcgRIII receptors. IgG3 and IgG1 activate
complement strongly, while IgG2 can only activate comple-
ment in high antigen concentrations and IgG4 does not
activate complement effectively [67]. Additionally, there is
potential for IgG subclasses to have different roles in
immunity, pathology, and allergy by their capacity to bind to
different cells via their receptors. IgG4 can bind to Fcg
receptor 1 (CD64) with lesser affinity then IgG1 and IgG4
and does not bind to FcgRII (CD32) or FcgRIII (CD16)
[81].
Thymus independent antigens, produced by B1 cells in
early foetal in early childhood, generate IgG of subclass IgG2
more than IgG1 or IgG3 antibodies [68, 69]. IgG4 antibodies
and IgE antibodies are produced to helminth infection but
also on exposure to allergens [67]. IgG4 production in
human, like IgE production is controlled largely by Th2 cells
producing IL-4 and IL-13 [82].
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As shown in Table 2, IgG4 levels in the serum of normal
individuals are quite low (60mg/dL). IgG4 does not bind
complement but actively inhibits immune precipitation and
complement activation by IgG1 antibodies [83] and thereby
not only fail to generate significant inflammation but can
intervene in inflammatory diseases. The lack of complement
and Fcg receptor binding and the relatively low concentration
of IgG4 in serum all suggest that this subclass of immunoglob-
ulin may have regulatory rather than inflammatory or antigen
clearance functions. IgG4 production, like IgE, is controlled by
T helper 2 cells through IL-4 and IL-13 [81]. IgG4 can bind to
Fcg receptor I (CD64) (though with a lower affinity than IgG1
or IgG3), which presents on monocytes, macrophages, and
neutrophils, but not to the other Fcg receptors (FcgRII/CD32,
FcgRIII/CD16) [82]. IgG4 does not link with complement and
does not bind well to Fcg receptors of any type. The lack of a
conventional IgG activity suggests the role of IgG4 is in
immunomodulation. However, elevated IgG4 antibodies are
associated with pathology. IgG4-related disease is a not
uncommon systemic, immune-mediated disease characterized
by organ specific IgG4-bearing plasma cells, mass lesion, or
unexplained enlargement, fibrosis, and sclerosis [84], particu-
larly in the pancreas, and the lacrimal, submandibular and
parotid glands lymphnodes, thyroid glands and lungs [85]. The
association of IgG4 with sclerosing diseases may be a bi-
product of excessive anti-inflammatory cytokines producing
expansion of IgG4-producing plasma cells [86], reflecting
dysregulation of T regulatory and Th2 cells rather than the
direct causation of fibrosis or sclerosis by IgG4.
Given that IgG4 is the least abundant immunoglobulin,
only some 4% approximately of the total IgG found in
serum, how is IgG4 able to effect the tollerization of
allergens? This may in part be due to the inherent instability
of IgG4 in which the interchain disulphide bonds in the
hinge region of IgG (Fig. 1) are labile, allowing the molecule
to split and exchangemonovalent halves. IgG subclasses have
more than 95% amino acid sequence identity but a serine
residue at position 228 (instead of a proline residue in this
position in IgG3) in the core hinge of IgG4 destabilizes
disulphide bridges between chains from adjacent cysteine
residues, allowing the formation of intrachain rather than
interchain disulphides and the separation of IgG4 molecules
into two halves [87, 88]. Interactions between the CH3
domains of antibody heavy chains in antibody assembly are
also critical in the formation of IgG. The CH3-CH3
interactions of IgG4 are weak, with the arginine at position
409 within the IgG4 CH3 domain of allowing exchange
between half molecules [89, 90]. It has been estimated that
up to 50% of IgG4 may be dissociated, existing as single
heavy chain and light chain molecules in serum. These
monovalent antibodies do not have the capacity to bind to
FC receptors and activate cells but do bind to allergens.
Monovalent antibody halves are able to undergo molecular
exchange, known as Fab-arm exchange (FAE), to create
antibodies with two specificities [91]. New IgG4 molecules
with two monovalent specificities are created with less
affinity to antigen, giving IgG4 an anti-inflammatory effect
[92]. By mopping up antigen but failing to trigger a cellular
response, IgG4 could not only deprive IgE antibodies of the
allergen to trigger an allergic response, but effectively nullify
the action of allergens in triggering cellular activation.
Half molecular exchange (one heavy and one light chain)
between two IgG4 molecules, generating new IgG4 anti-
bodies with bivalent reactivity, have been demonstrated in
vivo. Van der Neut Kolfschoten et al. [92] estimated that
50% of two IgG4 murine monoclonal antibodies against Fel
d1 antigen and Bet v1 antigen underwent Fab arm exchange
between when administered to immunodeficent SCID mice.
The presence of both k and l light chains on 21–33% of IgG4
molecules of five sera tested indicate that Fab exchange
occurs in a substantial portion of IgG4 in human serum [93].
Bivalent IgG4 molecules have much less affinity to either
antigen, reducing inflammation more effectively than
clearing antigen [94]. Both monovalent IgG4 halves and
Fab exchanged IgG4 antibodies, with weak dual specificity,
are unable to cross-link antigens and unable to form large
allergen immunocomplexes. Type III hypersensitivity re-
actions, in which small immune complexes are deposited in
tissues and fix complement, giving rise to inflammatory
responses and the attraction of leukocytes, constitute a
proportion of the pathology of many allergic diseases, such
as Farmer’s Lung, caused by the inhalation of fungal spores
from mouldy hay, Pigeon Fancier’s Lung, resulting from
powdery pigeon dung, Humidifier Fever, due to protozoans
growing in air-conditioning units, which generate allergic
alveolitis. Allergy to penicillin often involves interstitial
nephritis, a delayed skin rash, joint swelling, and respiratory
distress through type III hypersensitivity when immune
complexes are deposited in blood vessel walls and vascular
tissues. Antibodies to bee venom in novice beekeepers are
predominantly IgG1 that precipitate venom antigen (phos-
pholipase A2). With repeated bee stings, the IgG4 antibody
titer rises until it forms more than 90% of the response, at
which time immune complexes are not detected [83],
demonstrating that IgG4 antibodies are not only non-
precipitating, but also interfere with immune precipitation
by IgG1 antibodies. A similar protection against type III
hypersensitivity occurs with IgG4 antibodies to Fel d1 in
prolonged exposure to cats [95]. The low-affinity Fcg
receptors, FcgRII and FcgRIII (Table 2) are more potently
triggered by immune complexes than single IgG molecules
[96]. This wouldmean that the weak antigen binding of IgG4
monomers or bivalent FAE molecules would prevent the
formation of immune complexes of other IgG subclasses
with allergens and thereby reduce engagement of mast cells
and other hematopoietic cells in the pathology of allergy.
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While immunization typically stimulates IgG1 and IgG2
antibodies, allergy immunotherapy (AIT) is often associated
with the production of IgG4. An increase in blocking IgG4
antibodies has repeatedly correlated with the success of the
treatment of grass pollen hayfever and the relief of asthma
symptoms by immunotherapy [97–101]. IgG4 antibodies have
been shown to be effective in preventing even extreme allergic
reactions; passive immunization with immunoglobulins from
habitual beekeepers (with anti-venom antibodies almost
exclusively of the IgG4 subclass) protected against venom-
induced anaphylaxis [102]. The efficacy of IgG4 Fab exchange
in vivo has also been demonstrated; IgG4 antibodies to human
anti-acetyl choline receptor (AchR)blockedAChRdegradation
by IgG1 anti-AChR-specific monoclonal antibodies [92]. IgG4
antibodies to Fel d1 were strongly correlated with tolerance to
both mite and cat allergens while mite IgG1 antibodies
associatedwith asthma [103]. Further class switching to IgG4 in
allergy is a form of tolerance that has been suggested to explain
the observation that domestic animals decrease the risk of
asthma in allergic children [103]. These observations indicate
that development of IgG4may indeedoperate in vivo in allergic
children to reduce clinical symptoms of allergy due to reaction
with other sensitising allergens.
IgG4 mediated tolerance after AIT or SLIT (sublingual
immunotherapy) may be due to its function as a blocking
antibody, preventing the allergen causing degranulation of
IgE-bearing mast calls and basophils. AIT also stimulates a
complex of B and T cell responses to cope with allergic
symptoms: regulatory CD4- positive T cells (Tregs) with
anti-inflammatory functions are induced; lymphocytes,
monocytes, and dendritic cells secrete anti-inflammatory
IL10 and TGFb cytokines. AIT decreases the production of
proinflammatory mediators with reduced migration of mast
cells in target organs, IgA antibodies in mucosal surfaces or
blood IgG can lead to improvement of symptoms by
inhibiting binding of allergen to IgE on mast cells and
basophils [103]. As IgE-allergen ligation is also associated
with activation of T-helper (Th2) cells and IL-4 secretion,
IgG4 may also have an effect by modulating this secretion
indirectly. IgG4 has been reported to favour tolerance by
stimulating IL-10 production in regulatory T cells [92] as
well as B cells [104]. When IL10 was measured in after
intralymphatic inguinal injections of birch pollen or grass
pollen [105, 106] IL-10 increased in both cases. IL-10 was
shown to reduce proinflammatory cytokine release from
mast cells [107]. In addition, IL-10 downregulates eosino-
phil function and activity and suppresses IL-5 production by
human resting Th0 and Th2 cells [108]. IL-10 alsomodulates
of B cell Ig class switching in favour of IgG4 production
[109], generation the increasing IgG4/IgE ratio characteristic
of successful AIT treatment and naturally evolved tolerance
[110–112], indicating that the relative abundance of IgG4 is
at least one of the seminal events in the resolution of allergy.
Thus, three possibilities may explain the association of
IgG4 with favorable AIT and natural resolution of allergy
(Fig. 3). IgG4 antibodies may act as blocking antibodies,
protecting by blocking IgE-dependent allergen-induced
activation of mast cells (Fig. 3A). Blocking IgG4 antibodies
sequesters allergen so it no longer activates low affinity IgG
receptors on mast cells. IgG4 thereby interferes with the IgE-
allergen complex induced activation of Th2 cells, leading to
reduced activation of proinflammatory cells. IgG4 produc-
tion also induces T-regulatory cells to produce anti-
inflammatory factors like IL10 and TGF-b which induce
an increase in IgG4 production from germinal center B cells.
IL10 may be produced in an autocrine fashion from B cells
but allergen exposed DC and macrophages and T regulatory
cells exposed to IgG4 may contribute a significant propor-
tion when induced through FcgRIII receptors (Fig. 3B).
Thirdly, the unique monovalent nature of inhibitory
FcgRIIb receptors allows ligation with singe dissociated
Fab arms of IgG4-antigen complexes and overturn the
activational stimulation of basophils and B cells due to
allergen specific IgG1 and IgG3 antibodies (Fig. 3C).
FcgRIIB receptors, however, need to co-engage with
activating FcgRs and immune complexes [113] to inhibit
cell activation. Additionally, FcgRIIB receptors have little
expression onmast cells andmonocytes (Table 2) whichmay
limit the direct inhibitory action of IgG4 to antigen
presenting Langerhans and DCs and to preventing degran-
ulation of basophils in blood.
Different effector functions of IgG4 may be involved in
different forms of immunotherapy because it addresses a
wide range of allergic symptoms from allergic rhinocon-
junctivitis to anaphylaxis. The same mechanism cannot be
expected for all systems. Anaphylaxis is a rapid process that
cannot be prevented through the relatively slow process of T
regulatory cell activation but depends on fast-acting block-
ing antibodies. In contrast, reducing inflammation in the
airways is muchmore likely to involve regulatory T cells. The
significance of regulatory T cells in controlling allergy is
highlighted by the fact that Foxp3 (forkhead box P3, a
transcriptional regulator that binds to genes in the
development and function of regulatory T cells) mutation
in mice and humans leads to intense multi-organ inflam-
matory responses [85, 114]. Development of peripheral T
cell tolerance is also characterized by either the deletion or
anergy of allergen-specific T effector cells as well as the
generation of allergen-specific T regulatory cells, together
limiting the function of allergen-specific Th2 cells, mast cells,
and other effector cells. This would indicate that different
treatments might serve different purposes; treatment with an
allergenic peptide might favorably affect specific T-cell
clones but leave clones with reactivity to other allergens
unaffected. IL10 directed immunotherapy, on the other
hand has the potential to be incompletely allergen specific
T. H. Scott-Taylor et al. IgG in the induction, pathology, and resolution of allergy
© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 23
and favor the resolution of combinations of allergies. The
nature of the antigen preparation in AIT is also are
important, peptides must be multivalent and resistant to
degradation. Denatured allergens or peptides will not be
optimally effective in half molecular exchange (one heavy
and one light chain) between two antigen bound IgG4
molecules, or generating a new IgG4 with a bivalent
reactivity [94] that interferes with IgE cross-linking of
activating Fcg receptors.
Conclusions and Therapeutic Applications
of IgG4 Antibodies
Human sera contain a mixture of antibodies of different
classes and subclasses with a wide range of specificities. Most
allergens are internalized by antigen-presenting cells,
including B-2 cells in germinal centers, macrophages, and
dendritic cells, and digested to form peptide fragments
expressed on surface MHC class II molecules. CD4þ Th cells
differentiate when presented with a cognate antigen, secrete
cytokines, and stimulate the class switching in B cells. The
IgG subclass generated depends on the type of Th cell
response, particularly Th1 cells producing IFNg and class
switching to IgG1 and IgG3 antibodies and Th2 cells
producing IL-4 and IL-5 and class switching to IgG4 and IgE
antibodies [48]. Degranulation of mast cells and basophils
and the cellular conditions created by hypersensitivity type I
responses, and the subsequent activation and degranulation
of eosinophils, damage tissue, and influence the IgG subclass
toward IgE production, generating an atopic autocrine cycle
of cytokine and antibody polarisation [53]. The conditions
that cause class switching of mature B cells producing IgG1
or IgG3 antibody to allergens in atopic lymph nodes of,
children at risk, generating modification of Ig genes on
chromosome 22 to IgE production, sensitisingmast cells and
basophils for degranulation are still under debate. There is
evidence that the repetitive, multi-epitope nature, the
stability and indigestibility of allergenic proteins stimulates
the preformed IgG producing cells into further class-
switching on repeated encounters. There is also evidence
that Immature B cells may switch more directly from IgM to
IgE secretion when exposed to certain allergen conforma-
tions in early infancy and the suggestion that early exposure
to allergens accounts for higher rates of IgE production in
atopic and allergic children. Additionally, the genetic
influence of an atopic parent may shape the cytokine
induction of B cells in allergen specific germinal centers in
the same way as a lack of inflammatory experience in early
childhood has the potential to generate a tendency to
respond in a Th2 skewed immune response [115]. Atopic
individuals may be predisposed to make Th2 responses and
specifically predisposed to respond to some allergens than
normal. Studies of atopic families have identified regions on
chromosomes 11q, encoding the b subunit of the high-
Figure 3. Immunomodulation by IgG4. A: blocking of IgE antibodies. IgG4 antibodies dissociate, mop up free allergen and fail to trigger Fc receptors. B:
IL10 production by T regulatory cell, monocytes, macrophages, and DCs induces B cell production of IgG4. C: signaling through inhibitory FCgIIB
receptors. ITIM inhibitory stimulus of FCgIIB ligated receptors without crosslinking by half or whole IgG4 prevents mast cell activation through FcgIII.
¼ IgE, ¼ IgG1, ¼ IgG4 vs Fel d1, ¼ IgG4 vs Der p1.
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affinity IgE receptor and 5q whereas there is a cluster of
tightly linked genes including those for IL-3, IL-4, IL-5, IL-9,
IL-12, IL-13, GM-CSF, involved in IgE isotype switching,
eosinophil survival, and mast-cell proliferation, that appear
to be important in determining atopy. A genetic variant of
the IL-4 gene promoter region that increases expression of
reporter gene in experimental systems is associated with
raised IgE levels in atopic individuals. Certain HLA class II
allele association with allergy, for example, ragweed pollen
allergy with MHC II DRB11501, imply that presentation of
certain allergenic peptides induce stronger Th2 responses.
Most atopy associated genetic predispositions are related to
the polarization of Th2 cytokine responses to allergens.
Self-reactive IgG and IgE antibodies are commonly
detected in both allergic and autoimmune diseases and
contribute to the pathogenesis of BP, RA, SLE, and MS
[116]. IgG receptor cross-linking elicits mast cell activation
and plays a pathogenic role in allergy and autoimmunity.
Many of the self-antigens that react with IgE are homologs of
environmental antigens, including the actin binding protein,
serum albumin, collagen, and desmoplakin and are thought
to result from cross-reactivity [74]. It is possible that
inflammation due to mast cell, basophil and eosinophil
degranulation to environmental allergens induces tissue
damage and a Th2 dominated immune environment in
which these self-antigens, no longer sequestered from the
immune system, elicit an IgE response [78].
Evidently neither the induction, the pathology or the
resolution of allergy revolves entirely around specific IgE to
allergens. IgG antibodies play a role in the induction of
allergic symptoms and pathology of allergy and other
autoimmune diseases. IgG antibodies are involved in
induction an allergic response, are formulated to bind and
eliminate allergenic epitopes, are generated in oral therapy
that effectively ameliorates clinical sensitisation and may
also be the major means of natural resolution of allergy.
IgG4 may be effective in interrupting the cyclical
elaboration of atopic conditions that lead to prolongation
of allergic sensitization. IgG4 does not cross-link comple-
ment and does not bind efficiently to activatory Fcg
receptors but, due to the inhibitory action FcgIIb receptors,
can interrupt the cyclical induction of Th2 cytokine
polarization. IgG4 antibodiesmay act as blocking antibodies,
preventing IgE-dependent activation of mast cells and
interfering with IgG-allergen complex induced activation of
Th2 cells, leading to reduced activation of proinflammatory
cells. The IgG4 sequestration of allergen may be more
dependent on the weak association of bimodal FAE
antibodies as the monomeric form of IgG4 is close to the
glomerular filtration threshold (70 kDa) [117] and more
prone to degradation by serum proteases, reducing the half-
life (21 h) compared with wild-type IgG4 (13 days). The lack
of inhibitory FcgIIb receptors on mast cells [118], its poor
expression on monocytes and neutrophils, may limit the
direct inhibitory role of IgG4 on inflammatory cells.
However, FcgIIb is highly expressed on circulating B cells
and basophils and tissue macrophages and DCs which could
denote a role of IgG4 in immunomodulation of systemic
allergic reactions and the reduction of allergic responses in
lymph nodes.
Given that IgG4 is one of the cardinal signs of developing
immune tolerance and may be one of the most effective
means by which the immune system generates an escape
from the cyclical production of IgE and further Th2 cytokine
polarization, how can IgG4 antibodies be used therapeuti-
cally? It may be dangerous to promote IgG4 antibodies in all
disease. IgG4-related diseases can affect any organ but are
most common in the pancreas, and lacrimal, submandibu-
lar, and parotid glands. Patients with an IgG4-related disease
demonstrate high levels of IgG4 in their serum and organ
infiltration of IgG4-bearing plasma cells with consequent
fibrosis and sclerosis. In various forms of cancer IgG4 levels
correlate positively with T regulatory cells but negatively
correlate with cytotoxic T lymphocytes [119] supporting the
generation of IgG4 in immune tolerance in cancer.
Melanoma can trigger B cell expression of IL-10 and
VEGF, inducing production of IgG4 [120]. Several carcino-
mas and cancer cell lines produce IL-10 and FoxP3,
indicating that tumors may promote a biased Th2 response
promoting IgG4, but limiting immune responses and
enabling the escape from immune clearance. Therefore,
elevated serum IgG4 levels have been associated with poorer
prognosis in biliary tract cancers [121] and in malignant
melanoma [120, 122]. Preliminary clinical trials have
disclosed adverse reactions with some formulations of
IgG4 antibodies. For example, some volunteers involved in
the IgG4 anti-CD28 clinical trial with antibody TGN-41264
experienced a ‘‘cytokine storm’’ lead to hospitalization with
tomultiple organ dysfunction, possibly due to the binding of
IgG4 immunocomplexes with FcgRIIA and FcgRIII recep-
tors on T helper cells [123].
Nevertheless, the deficiency in triggering of many cellular
effector functions makes IgG4 an attractive therapeutic
monoclonal antibody format. Pembrolizumab and Nivolu-
mab, for example, both anti-PD-1 (programmed death-1)
IgG4 monoclonals in the USA for treatment of melanoma
since 2014, block the ligation of the immunoinhibitory PD-1
receptor on T-cells, but do not elicit ADCC or complement-
dependent cytotoxicity. Antibodies that target PD-1 and
CTLA-4 in cancer therapy are thought to act directly by
antagonising these inhibitory receptors, and there is no
significant evidence to indicate that engagement of Fcg
receptors plays any important role in their therapeutic
activity. As the principal inhibitory receptor targets of cancer
immunotherapy are expressed either on T cells or on antigen
presenting cells, IgG4 has been the isotype of choice in the
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formation of monoclonal antibody therapeutic reagents as
IgG4 does not cause the depletion of cytotoxic T cells or
APCs through Fc mediated mechanisms. Therefore, Nivo-
lumab and Pembrolizumab which are in use andMDX-1105
and BMS-663513 which target PD-L1 and CD137, respec-
tively, may have longer duration in serum owing to their
IgG4 isotype.
Based on the observation that IgG4 antibodies exchange
their Fab arms through a dynamic process that involves
separation of the two heavy chains and reassembly into the
full molecule, conditions were adapted to generate stable
bispecific IgG1 molecules by controlled FAE [124]. The
suitability of this process for commercial-scale manufactur-
ing was demonstrated by production of a bispecific IgG
against EGFR and CD20 (DuoBody) under controlled
reducing conditions, with more than 95% Fab arm exchange
on a kg scale [125]. However, both Pembrolizumab and
Nivolumab have been generated with a (IgG3) proline
residue at position 228 in their hinge regions to prevent
dissociation. Several IgG4 antibodies currently in clinical
trials, with wild-type or stabilized hinges, are directed against
cytokines to alleviate the symptoms of allergy or inflamma-
tion, including Reslizumab and Tralokinumab for the
treatment of asthma [126, 127] and Ixekizumab for the
treatment of psoriasis [128]. Reslizumab, approved in 2016,
binds to IL-5 with high affinity, inhibiting IL-5 signalling
and reducing the production and survival of eosinophils.
Tralokinumab neutralizes IL-13, a key respiratory cytokine
that drives inflammation, airway hyper-responsiveness, and
excessive mucus production in impaired lung function,
contributing to the severity and frequency of asthma attacks.
Ixekizumab neutralizes IL-17, a cytokine directly activates
keratinocyte genes including those for beta-defensins,
antimicrobial peptides (AMPs), and chemokines and
synergistically interacts with TNFa to generate psoriatic
skin lesions. These IgG4 antibodies act directly to neutralize
and antagonize the binding of the cytokines so that the
involvement of Fab antibody exchange in the action of these
monoclonal antibodies (mAb) is unlikely. Similarly, Dupi-
lumab, an anti-IL-4Ra IgG4 monoclonal antibody under-
going review evaluation for atopic dermatitis,
Galcanezumab an IgG4 antibody targeting calcitonin
gene-related peptide, being studied for use in patients
with severe migraines, and Fasinumab, an IgG4 mAb
targeting nerve growth factor [129], being evaluated in
phase 3 clinical studies as a treatment for osteoarthritis pain,
owe their probably action to direct interference with the
action of the target protein and not immunomodulation.
Similarly, Ibalizumab and PRO140, both new IgG4 mAb
undergoing evaluation as treatments for human immuno-
deficiency virus (HIV)-1 infection, act directly on viral
receptors on cells and owe their efficacy to interfering with
virus binding without disturbing the cells’ immunological
functions. Ibalizumab binds to the second extracellular
domain of CD4 [130], while PRO140 inhibits R5 CCR5-
tropic HIV by targeting the chemokine receptor CCR5 [131],
which acts as a co-receptor to viral entry of macrophages,
dendritic cells and memory T cells. GNbAC1, an IgG4 mAb
currently in stage II clinical trials for safety and pharmaco-
kinetics analysis, neutralize the expression of the envelope
protein of Mulitple Sclerosis Retrovirus [132], an endoge-
nous human retrovirus that has been linked with MS. Thus,
the unique capacity of IgG4 to form bivalent antibodies in
vivo through FAE or to block cell activation by weak Fc
occupation has not yet been exploited in the formulation of
monoclonal therapeutics.
Instead bivalent antibodies, sometimes involving IgG4,
are being formulated for a new generation of wide-ranging
therapeutics. A bivalent IgG4 antibody with arms specific to
factor IXa and factor X, termed hBS23, binds and brings
these two factors into juxtaposition, mimicking the cofactor
function of factor VIII to alleviating bleeding in hemophilia
A [133]. Due to the deregulation of multiple factors in many
diseases, bispecific antibodies engaging two targets offer
greater potential for therapeutic efficacy as well as
overcoming escape mechanisms observed in therapy of
single targets. The IgG4 monoclonal antibody Ibalizumab
was paired with half antibody anti-CD70 molecules by site-
directed mutagenesis [134] to create hybrid bivalent
antibody with preferential binding and selective depletion
of CD4þ/CD70þ T cells. A bispecific mAb that neutralizes
both IL-4 and IL-13 for the treatment of asthma, based on
the IgG4 antibody Lebrikizumab, generates higher titers than
its predecessor, an IgG1 bispecific antibody [135].
At least twelve bispecific mAbs are currently being
evaluated in clinical studies [136] and liable to be available
as therapeutics in the near future. With many methods
developed for conjugating monovalent antibody halves, few
of these mAbs involve IgG4 and few are directed against
allergy or are designed to block inflammation. The
monoclonal antibody treatment of allergy began with the
licensing of Omalizumab, an IgG1 mAb that binds
specifically to the CH3 domain of IgE, blocking its
interaction with FceRI on mast calls, basophils, and other
cells [137, 138]. Administration of Omalizumab reduces
FceRI receptor density on and the influx of cells involved in
allergic responses and, when as a treatment for asthma,
improved lung function and quality of life, and reduced the
need for corticosteroids [139]. Lowering free IgE levels may
downregulate the levels of IgE receptor expression density on
the surface of mast cells in time, but the ability of
Omalizumab to cause the dissociation of bound IgE is
more likely to explain the rapid and prolonged intervention
in chronic urticaria [140]. The involvement of IgE in other
diseases has started the assessment of Omalizumab in allergic
rhinitis, atopic dermatitis, food allergies, mastocytosis, and
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eosinophilic gastrointestinal disease [141, 142]. However,
there are serious drawbacks to the use of Omalizumab; it
costs $10–30,000 annually to treat an individual but
moreover it can cause anaphylaxis and fatal autoimmune
reactions at a rate of 1–2 per thousand, prompting the FDA
to have a black-box warning placed on Omalizumab [143].
Other mAbs have also been tested in allergic disorders,
including agents Th2 and Th2-promoting cytokines, IL-4,
IL-5, IL-9, IL-13, IL-31, and thymic stromal lymphopoietin
(TSLP) [144]. Dupilumab, a human anti-IL-4 a receptor
mAb (IgG4) was shown to reduce asthma exacerbations,
improve lung functions and reduce Th2-associated inflam-
matory markers in patients with persistent, moderate-to-
severe asthma [145]. In AD patients, dupilumab decreased
expression of genes upregulated in AD lesions by 26% [146]
and four further clinical studies in atopic dermatitis, and in
asthma, are in process. Anti-IL-5 neutralizing mAbs
Mepolizumab and Reslizumab and Benralizumab that
blocks the IL-5 a receptor have been developed [147].
Reslizumab, targeting IL-5, a cytokine involved in the
maturation, recruitment, and activation of eosinophils,
improved lung function, asthma symptoms and quality of
life in two Phase 3 studies, without significant side effects
[148]. TSLP is an epithelial cytokine strongly associated with
symptoms and severity of the with asthma and AD [149].
mAb AMG 157, that prevents TSLP receptor binding,
reduced bronchoconstriction, eosinophil numbers, and
indexes of airway inflammation and further trials for severe
asthma and AD are underway. Preliminary investigations of
mAbs to IL-9, IL-13, IL-17, and IL-4/IL-13 are ongoing but
optimized formulations of mAb therapy for allergy or
asthma are still several years away from clinical use [150].
The different properties of IgG isotypes, resulting from
differences in binding to serum complement proteins and
Fcg receptors on immune effector cells will continue to be
utilized in formulating antibody therapies specific to various
targets in allergy. The engagement of IgG1 isotype antibodies
of complement proteins and to trigger antibody-dependent
cellular cytotoxicity and the ability of IgG4 isotype
antibodies to block Fcg receptors on immune cells could
provide a broad range of therapeutic antibodies with
differing effector functions to overcome the lack of
improvements with conventional therapy. The use of
mAbs that target inhibitory signals rather than blocking
activating could be an additional strategy to explore in
overcoming allergic responses.
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